Teleflex Announces First Quarter 2014 Earnings Conference Call Information
Business Wire - Wed Apr 16, 6:00AM CDT
Teleflex Incorporated (NYSE: TFX) announced today that financial results for the first quarter 2014 will be released before market open on Wednesday, April 30, 2014. An investor conference call will be held at 8:00 a.m. (ET) on Wednesday, April 30, 2014. The call can be accessed through a live audio webcast on the company's website, www.teleflex.com. An audio replay of the call will also be available on the website from April 30 at 12:00 p.m. (ET) to May 7, 2014 at 11:59 p.m. (ET) by calling 888-286-8010 (U.S./Canada) or 617-801-6888 (International), Passcode: 11286884.
Global Peripheral I.V. Catheter Market 2014-2018 with Braun, CR Bard, Smiths Medical, Teleflex, Terumo & Becton Dickension Dominating
M2 - Wed Apr 16, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zzpzkc/global_peripheral) has announced the addition of the "Global Peripheral I.V. Catheter Market 2014-2018 with Braun, CR Bard, Smiths Medical, Teleflex, Terumo & Becton Dickension Dominating" report to their offering. The Global Peripheral I.V. Catheter market to grow at a CAGR of 8.08 percent over the period 2013-2018. The Global Peripheral I.V. Catheter market is driven by several factors, a major one being the increasing aging population. The elderly require peripheral I.V. catheters to deliver drugs and nutrition, and for taking blood samples. Also, WHO statistics state that nearly 2 billion people will be aged 60 years and above by 2050, which will also enhance the market's growth in the future. One of the emerging trends in the market is the adoption of power-injectable closed catheters for the injection of contrast media during CT imaging. CT imaging requires a contrast media to be used for enhanced visualization during diagnostic procedures. However, the catheter must be strong enough to withstand pressures that can be more than 300 psi. Hence, power-injectable closed catheters are used for CT imaging as they are made of polyurethane material, which is much stronger than silicone and can withstand high pressures with a minimal decrease in flexibility. For example, BD Nexiva closed I.V. catheter of BD helps inject contrast media for contrast-enhanced CT scans. Further, the report states that the high cost of integrated/closed catheters is proving to be a hindrance to the adoption of these catheters, particularly in developing countries. Closed catheters are offered at an average selling price of more than US$4, which makes their adoption quite difficult in developing countries. Key Vendors - B. Braun Melsungen AG - Becton, Dickenson and Co. - C.R. Bard Inc. - Smiths Medical - Tangent Medical Technologies - Teleflex Inc. - Terumo Corp. Other Prominent Vendors - Argon Medical Devices Inc. - Medical Components Inc. - Vascular Pathways Inc. - VIGMED AB - Vygon SA Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Global Vascular Access Catheter Market Segmentation - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zz...peripheral
Balanced View of Luminex Corporation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 5:30PM CDT
Luminex is optimistic about the life science research market and foresees continued favorable trends with respect to demand from its clinical customers.
Shares of TFX Up 7.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Apr 10, 5:12PM CDT
SmarTrend identified an Uptrend for Teleflex (NYSE:TFX) on February 13th, 2014 at $95.22. In approximately 2 months, Teleflex has returned 7.56% as of today's recent price of $102.41.
Certifications, Authorizations, Stock Updates, and Upcoming Conferences - Analyst Notes on Edwards Lifesciences, Alkermes, ResMed, Auxilium, and Teleflex
PR Newswire - Thu Apr 10, 11:23AM CDT
Today, Analysts Review released its analysts' notes regarding Edwards Lifesciences Corp (NYSE: EW), Alkermes Plc (NASDAQ: ALKS), ResMed Inc. (NYSE: RMD), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and Teleflex Incorporated (NYSE: TFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Teleflex to Showcase Urological Products at the European Association of Urology's 29th Annual Congress
Business Wire - Tue Apr 08, 6:00AM CDT
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, will showcase a number of urological products for customers in the hospital and home care markets at the European Association of Urology's ("EAU"
Uptrend Call Working As Teleflex Stock Rises 13.3% (TFX)
Comtex SmarTrend(R) - Thu Apr 03, 11:20AM CDT
SmarTrend identified an Uptrend for Teleflex (NYSE:TFX) on February 13th, 2014 at $95.22. In approximately 2 months, Teleflex has returned 13.32% as of today's recent price of $107.90.
Study: Teleflex Catheter Reduces Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 6:20PM CDT
The study, conducted by Leonardo Lorente M.D., Ph.D. and his colleagues independently, found that the Teleflex's ARROW catheter with ARROWg+ard Blue PLUS Technology lowers the risk of catheter-related bloodstream infections.
Teleflex (TFX) Rises to $100: How Much Higher Can It Go? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:49AM CDT
Teleflex crosses a fresh high breaching the psychologically-important $100 per share mark for the first time
Teleflex Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 1:50PM CDT
An encouraging guidance, increased M&A activity and stronger operating leverage represent a potential upside for Teleflex going forward.
Teleflex Highlights ARROWg+ard Blue PLUS(R) Antimicrobial Central Venous Catheter (CVC) Study, Which Shows Reduced Infections and Related Costs
Business Wire - Tue Mar 25, 8:02AM CDT
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that newly published research has reaffirmed that the ARROW Central Venous Catheter (CVC) with ARROWg+ard Blue PLUS(R) Technology reduces the incidence of catheter-related bloodstream infections (CRBSIs) and reduces direct costs related to treatment of these potentially deadly infections.(1)
Teleflex Hits New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 12:35PM CDT
Shares of Teleflex started escalating following its impressive 2013-fourth quarter results and promising 2014 guidance as well as its recent 510(k) clearance from U.S. Food and Drug Administration.
FDA Approvals, Financial Highlights, Restated Treatment Indications, and Updates on Product Pipelines - Analyst Notes on Bristol-Myers Squibb, Galena, Teleflex, GW Pharmaceuticals, and CytRx
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Bristol-Myers Squibb Company (NYSE: BMY), Galena Biopharma, Inc. (NASDAQ: GALE), Teleflex Incorporated (NYSE: TFX), GW Pharmaceuticals plc (NASDAQ: GWPH), and CytRx Corporation (NASDAQ: CYTR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Teleflex Gets 510(k) Clearance for Restated Indications - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:00PM CDT
EZ-IO Vascular Access System has been developed by Vidacare Corporation, acquired by Teleflex in December last year.
Teleflex announces Restated Indications for Use for EZ-IO(R) Vascular Access System
Business Wire - Mon Mar 17, 4:00PM CDT
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced FDA 510(k) clearance for restated Indications for Use of the EZ-IO(R) Vascular Access System. The EZ-IO(R) 25 mm Needle Set is now indicated for patients 3 kg or over. Teleflex recently announced its acquisition of Vidacare Corporation, developer of the EZ-IO(R) Vascular Access System. Vidacare is a leading provider of intraosseous (IO), or inside the bone access devices.
Teleflex Earnings In Retrospect: Up 1.7% in the Last 17 Days (TFX)
Comtex SmarTrend(R) - Mon Mar 10, 7:27AM CDT
Two weeks ago on February 21st, 2014 Teleflex (NYSE:TFX) reported earnings and analysts, on average, expected earnings of $1.28 on sales of $437.7 million. The company actually reported EPS of $1.36 on sales of $450.5 million, beating EPS estimates by $0.08 and beating revenue estimates by $12.9 million. Shares of Teleflex have climbed from $101.19 to $102.89, representing a gain of 1.7% since the company reported earnings 17 days ago.
Stock Price Movements, Official Platinum Sponsor Status, Conference Schedules, Appointments and Clinical Trial Results - Analyst Notes on Intuitive, Agilent, Teleflex, WuXi PharmaTech, and Pacira
PR Newswire - Wed Mar 05, 3:00PM CST
Editor Note: For more information about this release, please scroll to bottom.
Teleflex Beats on Q4 Earnings, Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 12:50PM CST
Following the favorable earnings announcement, shares of Teleflex rose 0.8% till the last closing date.
Biotie: Change in the number of votes
Thomson Reuters ONE - Fri Feb 28, 12:51AM CST
BIOTIE THERAPIES CORP. Stock Exchange Release 28 February 2014 AT 8.50 AM